Andrew Staron, MD, Boston Medical Centre, Boston, MA, discusses the assessment of minimal residual disease (MRD) using multiparametric flow cytometry in treated patients with AL amyloidosis.
Eli Muchtar, MD, Mayo Clinic, Rochester, MN, discusses localized amyloidosis compared to systemic amyloidosis, with localized amyloidosis diagnosis based on symptoms and site of localized disease.
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the goal of therapy in immunoglobulin light chain (AL) amyloidosis and what predicts the best outcome, highlighting that free light chain ratio should not be used as a criterion or endpoint of therapy.
Joel Buxbaum, MD, Scripps Research, La Jolla, CA, discusses in detail the genetic signatures associated with hereditary ATTR amyloidosis. Specifically discussed is how the pattern of penetrance of ATTR amyloidosis is dependant on a small number of genes (20-30 genes).
Mathew Maurer, MD, Columbia University, New York, NY, discusses the results of the DISCOVERY screening study (NCT02252653), which investigated the prevalence of TTR mutations in patients suspected of having cardiac amyloidosis.
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the burning questions in the use of autologous stem cell transplant (ASCT) in AL amyloidosis.
Autologous stem cell transplant (ASCT) has been utilized in the management of immunoglobulin light chain (AL) amyloidosis for several decades. Eli Muchtar, MD, Mayo Clinic, Rochester, MN, discusses the burning questions in the use of ASCT in AL amyloidosis.
Joan Blade, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses amyloidosis classification, and epidemiology. Specifically highlighted are AL amyloidosis, systemic amyloidosis, ATTR amyloidosis, and other forms of secondary amyloidosis related to inflammatory processes.
Following a special lecture at the 2020 Virtual International Symposium on Amyloidosis, Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy discusses the aim for an amyloid disease cure.
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the utilization of a multidisciplinary treatment approach in the management of patients with AL amyloidosis.